Beta-Trace Protein May Have Potential Uses As Novel Biomarker For CIDP And Guillain-Barré Syndrome, Study Finds

Rare Disease Advisor (3/20, Murphy) reports, “Beta-trace protein (BTP) may have potential uses as a novel biomarker for chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-Barré syndrome (GBS), according to a study.” In the study, “elevated levels of BTP in cerebrospinal fluid (CSF) and plasma were observed before treatment initiation in patients with CIDP when compared to all controls and in GBS when compared to disease-free controls.” The findings were published in the Journal of Neurological Sciences.